Inhibikase Therapeutics (IKT) Stock Insights

IKT price $1.60 +0.03 +1.91%

Ticker
IKT
Price
$1.60
Change
+0.03 +1.91%
Market cap ?
$223.26M
P/E ?
-3.35
Forward P/E ?
6.60
Dividend yield ?
0.00%
Beta ?
0.90
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
57
Quality
48
Growth
100

Stocklytics score rationale: value 57, quality 48, growth 100.

Financials

2016201720182019202020212022202320242025
967386206093740409551122740698468310060512344026050000

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate…

Fair value

IKT fair value $5.24. Price $1.60. Price is 69% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 26.48K. Growth 3.13%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 9.24% (beta 0.9). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 139.54M. Net debt -139.22M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare IKT

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-13—-0.11—187.50K
2026-08-11-0.11-0.11——
2026-05-12-0.10-0.10——
2026-03-26-0.09-0.12——
2025-11-14-0.13-0.13——
2025-08-14-0.11-0.09——
2025-05-14-0.15-0.11——
2025-03-270.88-0.10——
2024-11-14-0.65-0.38——
2024-08-14-0.66-0.58——
2024-05-15-0.73-0.79——
2024-03-27-0.63-0.781—
2023-11-14-0.86-1.1279.57K—
2023-08-14-1.11-0.92116.41K—
2023-05-16-0.96-0.1564.52K—
2023-03-31-1.02-1.1453.44K—
2022-11-14-1.08-0.187.29K200.00K
2022-08-12-1.08-0.196.55K300.00K
2022-05-16-1.08-0.1746.03K300.00K
2022-03-31-1.20-0.171.94K300.00K
2021-11-15-1.08-0.14328.46K300.00K
2021-08-16-1.32-0.381.36M300.00K
2021-05-17-1.56—1.41M—
2021-03-31-0.87—698.47K—
2020-09-30-0.49—37.68K—
2020-06-30-0.31—219.59K—
2020-03-31-0.40—270.79K—
2019-12-31-0.32—240.28K—
2019-09-30-0.89—124.43K—
2019-06-30-1.72—166.93K—
2019-03-31-1.27—591.10K—
2018-12-31-0.74—1.35M—
2018-03-31-0.10—691.20K—
2017-12-310.03—797.40K—
2017-03-31-0.14—247.38K—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-19Wasserman Scott M.Buy310.00K$1.65509.95K
2026-10-19Wasserman Scott M.Other0——
2026-07-30BERMAN DENNIS NBuy21.85K$1.2627.54K
2026-07-30BERMAN DENNIS NSell21.85K$1.2627.54K
2026-07-29RA CAPITAL MANAGEMENT, L.P.Buy18.03M$0.0018.03K
2026-07-29RA CAPITAL MANAGEMENT, L.P.Sell18.03M$0.0018.03K
2026-07-10RA CAPITAL MANAGEMENT, L.P.Other0——
2026-06-26BERMAN DENNIS NBuy155.00K$1.91296.05K
2026-06-26Canner DavidBuy155.00K$1.91296.05K
2026-06-26Kush ArvindBuy155.00K$1.91296.05K
2026-06-26Bellini RobertoBuy155.00K$1.91296.05K
2026-06-26Aurentz VincentBuy155.00K$1.91296.05K
2026-06-26Munshi AmitBuy155.00K$1.91296.05K
2026-02-21Aurentz VincentSell255.30K——
2026-02-21Cabell ChristopherSell338.28K——
2026-02-21Munshi AmitSell19.09K——
2026-01-05Iwicki Mark TBuy4.98M$2.0110.02M
2026-01-05Cabell ChristopherBuy900.12K$2.011.81M
2026-01-05McIntyre DavidBuy986.32K$2.011.98M
2025-11-21Sands Capital Life Sciences Pulse Fund II, L.P.Buy2.07M$1.453.00M
2025-06-30Aurentz VincentBuy108.18K$1.95210.94K
2025-06-30Canner DavidBuy108.18K$1.95210.94K
2025-06-30Munshi AmitBuy108.18K$1.95210.94K
2025-06-30Kush ArvindBuy108.18K$1.95210.94K
2025-06-30BERMAN DENNIS NBuy108.18K$1.95210.94K
2025-06-30Bellini RobertoBuy108.18K$1.95210.94K
2025-06-06Sands Capital Life Sciences Pulse Fund II, L.P.Other0——
2025-04-14McIntyre DavidBuy1.78M$2.003.55M
2025-04-14McIntyre DavidOther0——
2025-02-21Cabell ChristopherOther0——
2025-02-21Aurentz VincentOther0——
2025-02-21Munshi AmitBuy57.27K——
2025-02-21Cabell ChristopherBuy1.10M$2.973.27M
2025-02-21Iwicki Mark TBuy602.35K$2.971.79M
2025-02-21Aurentz VincentBuy134.43K$2.97399.25K
2025-02-21Cabell ChristopherBuy1.10M$2.232.45M
2025-02-21Aurentz VincentBuy134.43K$2.23299.77K
2025-02-21Iwicki Mark TBuy602.35K$2.231.34M
2025-02-21Cabell ChristopherOther0——
2025-02-21Aurentz VincentOther0——
2025-02-17Iwicki Mark TBuy1.79M$2.354.22M
2025-02-14Iwicki Mark TBuy4.37M$2.3510.28M
2025-02-14Iwicki Mark TOther0——
2025-02-14Kush ArvindBuy116.58K$2.35273.97K
2025-02-14Kush ArvindBuy56.60K$2.35133.01K
2025-02-14Bellini RobertoBuy116.58K$2.35273.97K
2025-02-14Bellini RobertoBuy73.58K$2.35172.91K
2025-02-14Freeman Roy LesterBuy22.64K$2.3553.20K
2025-02-14Munshi AmitBuy116.58K$2.35273.97K
2025-02-14Munshi AmitBuy56.60K$2.35133.01K
2025-02-14Canner DavidBuy116.58K$2.35273.97K
2025-02-14Canner DavidBuy22.64K$2.3553.20K
2025-02-14BERMAN DENNIS NBuy39.62K$2.3593.11K
2025-01-21Lees-Rolfe GarthBuy90.00K$1.26113.40K
2025-01-21Lees-Rolfe GarthBuy5.83K$1.267.35K
2025-01-21Lees-Rolfe GarthSell90.00K$2.16194.40K
2025-01-21Lees-Rolfe GarthSell5.83K$3.7922.11K
2025-01-21Freeman Roy LesterBuy30.00K$1.2637.80K
2025-01-21Freeman Roy LesterBuy21.85K$1.2627.54K
2025-01-21Freeman Roy LesterBuy6.67K$1.268.40K
2025-01-21Freeman Roy LesterBuy3.78K$1.264.76K
2025-01-21Freeman Roy LesterBuy1.14K$1.261.43K
2025-01-21Freeman Roy LesterSell6.67K$3.6124.07K
2025-01-21Freeman Roy LesterSell21.85K$33.43730.58K
2025-01-21Freeman Roy LesterSell1.14K$60.0068.28K
2025-01-21Freeman Roy LesterSell3.78K$17.5266.23K
2025-01-21Freeman Roy LesterSell6.67K$4.8632.40K
2025-01-21Freeman Roy LesterSell30.00K$1.5446.20K
2025-01-21Werner Milton H.Buy45.00K$1.2656.70K
2025-01-21Werner Milton H.Buy35.00K$1.2644.10K
2025-01-21BERMAN DENNIS NBuy30.00K$1.2637.80K
2025-01-21BERMAN DENNIS NBuy21.85K$1.2627.54K
2025-01-21Werner Milton H.Buy20.83K$1.2626.25K
2025-01-21Werner Milton H.Buy16.67K$1.2621.00K
2025-01-21BERMAN DENNIS NBuy6.67K$1.268.40K
2025-01-21BERMAN DENNIS NBuy3.78K$1.264.76K
2025-01-21Werner Milton H.Buy3.64K$1.264.59K
2025-01-21BERMAN DENNIS NBuy1.14K$1.261.43K
2025-01-21Werner Milton H.Sell3.64K$33.43121.79K
2025-01-21Werner Milton H.Sell3.64K$13.8650.49K
2025-01-21BERMAN DENNIS NSell21.85K$33.43730.58K
2025-01-21Werner Milton H.Sell35.00K$4.44155.40K
2025-01-21BERMAN DENNIS NSell6.67K$4.8632.40K
2025-01-21BERMAN DENNIS NSell6.67K$3.6124.07K
2025-01-21Werner Milton H.Sell45.00K$2.1697.20K
2025-01-21BERMAN DENNIS NSell3.78K$17.5266.23K
2025-01-21BERMAN DENNIS NSell30.00K$1.5446.20K
2025-01-21BERMAN DENNIS NSell1.14K$60.0068.28K
2025-01-21Werner Milton H.Sell20.83K$6.42133.75K
2025-01-21Werner Milton H.Sell16.67K$60.001.00M
2025-01-21Werner Milton H.Sell3.64K$28.76104.77K
2025-01-03Werner Milton H.Buy5.32M$1.266.70M
2025-01-03Werner Milton H.Buy4.06M$1.586.41M
2025-01-03Werner Milton H.Buy2.21M$1.453.20M
2025-01-03Lees-Rolfe GarthBuy470.86K$1.26593.28K
2025-01-03Lees-Rolfe GarthBuy432.85K$1.58683.91K
2025-01-03Lees-Rolfe GarthBuy235.38K$1.45341.31K
2025-01-03Freeman Roy LesterBuy344.45K$1.26434.01K
2025-01-03Freeman Roy LesterBuy316.65K$1.58500.30K
2025-01-03Freeman Roy LesterBuy172.19K$1.45249.68K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 107, holders +3 vs prior quarter. Ownership 67.67%.

HolderSharesChangeChange %Value
SANDS CAPITAL ALTERNATIVES, LLC13.02M00.00%26.43M
SOLEUS CAPITAL MANAGEMENT, L.P.10.88M00.00%22.08M
TRAILS EDGE CAPITAL PARTNERS, LP9.05M993.97K+12.34%18.37M
FAIRMOUNT FUNDS MANAGEMENT LLC8.62M00.00%17.51M
BLACKROCK, INC.7.77M1.46M+23.24%15.77M
ADAR1 CAPITAL MANAGEMENT, LLC7.39M780.63K+11.82%15.00M
BLACKSTONE INC.5.94M00.00%12.05M
SIREN, L.L.C.5.85M00.00%11.88M
COMMODORE CAPITAL LP5.40M00.00%10.96M
VANGUARD CAPITAL MANAGEMENT LLC4.94M484.69K+10.89%10.02M
MILLENNIUM MANAGEMENT LLC4.03M1.10M+37.57%8.18M
SATURN V CAPITAL MANAGEMENT LP3.87M5.61K+0.15%7.85M
KALEHUA CAPITAL MANAGEMENT LLC3.82M00.00%7.76M
SPRUCE STREET CAPITAL LP3.58M00.00%7.27M
SQUADRON CAPITAL MANAGEMENT LLC3.00M-500.00K-14.29%6.09M
NANTAHALA CAPITAL MANAGEMENT, LLC2.70M00.00%5.48M
GEODE CAPITAL MANAGEMENT, LLC2.61M436.94K+20.13%5.29M
STATE STREET CORP1.91M223.28K+13.24%3.88M
SUMMITTX CAPITAL, L.P.1.78M255.73K+16.77%3.61M
INTEGRAL HEALTH ASSET MANAGEMENT, LLC1.35M00.00%2.74M
NORTHERN TRUST CORP878.59K159.78K+22.23%1.78M
VANGUARD PORTFOLIO MANAGEMENT LLC809.49K191.76K+31.04%1.64M
TWO SIGMA INVESTMENTS, LP806.26K-41.35K-4.88%1.64M
SPHERA FUNDS MANAGEMENT LTD.649.31K649.31KNew1.32M
VANGUARD FIDUCIARY TRUST CO607.26K40.26K+7.10%1.23M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Inhibikase Therapeutics (IKT) Stock Insights

IKT$1.60+0.03 +1.91%

$223.26M

Market Cap

-3.35

P/E

6.60

Forward P/E

68

Score

Price History